Navigation Links
Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone
Date:6/27/2011

THOUSAND OAKS, Calif., June 27, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand the indication for XGEVA® (denosumab) to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases. If approved, XGEVA would be the first therapy licensed to prevent or delay the spread of cancer to the bone.

The sBLA submission is based on a pivotal Phase 3 Study ('147) evaluating XGEVA versus placebo in 1,432 men with castrate-resistant prostate cancer. Results of the '147 study demonstrate that XGEVA significantly prolonged bone metastasis-free survival by more than four months compared with placebo (29.5 versus 25.2 months, respectively) in men with castrate-resistant prostate cancer that had not yet spread to the bone.  Bone metastasis-free survival is a composite measure of the development of bone metastases or death.

"The successful outcome of this study provides clinical evidence supporting the view that tumors activate the RANK Ligand pathway to penetrate bone," said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen.  "XGEVA has the potential to become a significant advance for patients with castrate-resistant prostate cancer who currently have no treatment options to help prevent the spread of cancer to their bones."

Bone is one of the most common places for cancer to spread. In fact, up to 90 percent of men with advanced prostate cancer will have their tumor spread to the bone.(i),(ii),(iii) With effective therapies now in place for both early (castrate-sensitive) prostate cancer and advanced (castrate-resistant) metastatic prostate cancer, there is a gap in the treatment plan for those patients who are castrate-resistant but have n
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgen Announces Webcast of 2008 Third Quarter Financial Results
2. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
3. Call for Applications: The Amgen Award for Science Teaching Excellence
4. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
5. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
6. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
7. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
8. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
9. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
10. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
11. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014  Decision Resources Group finds that ... and Mexico currently ... newly approved agents, the anticipated label extension of ... launch of emerging biologics will substantially increase the ... emerging IL-5 inhibitors will introduce a new dynamic to ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Pursuit ... selling optimization technology and services for Life Sciences ... “Grading Pharma’s Use of New Commercial Sales Models” ... & Analytics. , The article examines some innovative ... that are being tested in the pharmaceutical market. ...
(Date:8/20/2014)... Aug. 20, 2014 Clintrax Global, Inc., ... in Raleigh, NC , recently ... as Vice President of Administration. ... all corporate processes, including their alignment with company ... Brad worked as an HR executive, specializing in ...
(Date:8/20/2014)... High performance computing (HPC) will be ... climate and Earth system model to address the ... Eight national laboratories, including Lawrence Livermore , ... Atmospheric Research, four academic institutions and one private-sector ... laboratories include Argonne, Brookhaven, Lawrence Berkeley, Los Alamos, ...
Breaking Biology Technology:Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2Clintrax Global, Inc. Announces Addition to Executive Team 2New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3
... No Child Should Die of Diabetes, BRUSSELS, October ... it is bringing together key opinion,leaders to push for ... diabetes in developing countries without access to care., ... in the,Developing World, will be held on Saturday, October ...
... Therapeutics is,presenting new data today representing an ... to enhance outcomes in patients,suffering from lower ... "Local Catheter-Directed Elastase Therapy: A Novel,Approach to ... at the 20th,annual Transcatheter Cardiovascular Therapeutics (TCT) ...
... risk of basal,cell carcinoma, and are integrated into ... Oct. 13 Scientists at,deCODE genetics (Nasdaq: ... of two single-letter variations in the human genome ... the most common cancer among,people of European ancestry. ...
Cached Biology Technology:International Diabetes Federation Calls for Global Action to Keep All Children With Diabetes Alive 2International Diabetes Federation Calls for Global Action to Keep All Children With Diabetes Alive 3Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008 2deCODE Discovery Sheds Light on Risk of the Most Common Form of Skin Cancer 2deCODE Discovery Sheds Light on Risk of the Most Common Form of Skin Cancer 3deCODE Discovery Sheds Light on Risk of the Most Common Form of Skin Cancer 4
(Date:8/21/2014)... landmark study aimed at improving the food intake, health ... care homes is among three projects at the University ... from the Canadian Institutes of Health Research (CIHR). ... Health Sciences at Waterloo, and a Schlegel research chair ... years to investigate why many Canadians living in long-term ...
(Date:8/21/2014)... WHEN: , Saturday to Wednesday, Oct. 18-22, 2014 ... 111 W. Harbor Drive, San Diego, CA 92101 ... sessions and other presentations of the latest research ... Opening plenary session featuring high-scoring abstracts on rare ... of various cancers, and treatment for sun sensitivity ...
(Date:8/21/2014)... developed a novel and versatile modeling strategy to simulate ... materials as well as for studying polyelectrolytes, including DNA ... model much larger and more complex polyelectrolyte systems, and ... lead author of a paper on the work and ... Science and Engineering. "This is a big step forward ...
Breaking Biology News(10 mins):Grants will fund landmark aging research at Waterloo 2American Society of Human Genetics 2014 Annual Meeting 2Researchers develop models to study polyelectrolytes, including DNA and RNA 2
... announced today its plans to launch a new cancer ... women with advanced stage ovarian cancer. This innovative treatment ... and developed by AVAX Technologies, Inc. (OTCMarket: AVXT.OB). ... is to help our patients win the battle against ...
... The new in-vitro technique pioneered by Dr Amanda Hayes ... directly exposes human cells to airborne toxicants and measures ... polyester membrane inside a small diffusion chamber and then ... as one hour's exposure, they can study cell growth ...
... some women seem to be more ill-tempered than others? ... as anger, hostility and aggression may be genetic, rooted ... Ph.D., of the Cardiovascular Behavioral Medicine Program at the ... the American Psychosomatic Society's Annual Meeting, held in Budapest, ...
Cached Biology News:Soft-cell approach cuts animal tests 2Soft-cell approach cuts animal tests 3
... Detection System combines the indirect labeling ... and Signets unique formulation of ultra ... reliablility. Signet reagents will achieve excellent ... automated protocols. ,Signets USA Detection reagents ...
... Each Signet Level 2 Detection System ... avidin-biotin chemical bonding principle and Signets ... provide sensitivity, specificity and reliablility. Signet ... in both manual and automated protocols. ...
XPMC2H Immunogen: XPMC2H (NP_065118, 323 a.a. ~ 423 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
6X DNA Gel Loading Buffer is intended for gel electrophoresis of DNA fragments or PCR products....
Biology Products: